Overall rank by patents
#34,831
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Clarity Pharmaceuticals Ltd
USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
7
Total patents granted
4
CPC technology areas
21.9
Avg claims per patent
-
5-year filing velocity
The verdict
Clarity holds 7 US patents across 4 technology areas, rank #34,831 of 50,000 tracked assignees.
- #34,831
- of 50,000 US assignees by volume
- Top 19%
- by Innovation Score (47.4/100)
- 21.9
- avg claims per patent
Portfolio overview
Clarity Pharmaceuticals Ltd has been granted 7 US utility patents between 2021 and 2025, placing Clarity Pharmaceuticals Ltd at rank #34,831 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Clarity Pharmaceuticals Ltd is one of the more focused assignees in the PatentsView dataset. By volume, Clarity sits between Cirrent, Inc. (7 patents, rank #34,827) and Clean Train Propulsion (7 patents, rank #34,835) - the closest US assignees by grant volume. The composite Innovation Score of 47.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Clarity Pharmaceuticals Ltd's 21.9 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Clarity Pharmaceuticals Ltd against peers pursuing similar technology classes.
Who files at Clarity's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Cirrent
Cirrent, Inc.
7 patents
- Citigroup Global…
Citigroup Global Markets Inc.
7 patents
- City Universsity…
City, Universsity of London
7 patents
- Clantech
Clantech, Inc.
7 patents
- Clarus Therapeuti…
Clarus Therapeutics, Inc.
7 patents
- Clean Air-enginee…
Clean Air-Engineering—Maritime, Inc.
7 patents
- Clean Diesel (Cdt…
Clean Diesel Technologies, Inc. (CDTi)
7 patents
- Clean Train Propu…
Clean Train Propulsion
7 patents
- Clarity Pharmaceu… ◀
Clarity Pharmaceuticals Ltd
7 patents
What this shows Clarity holds 7 patents at rank #34,831, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Clarity
By rank, the assignees closest to #34,831 in granted patent volume.
- Cirrent, Inc. #34,827 · 7 patents
- Citigroup Global Markets Inc. #34,828 · 7 patents
- City, Universsity Of London #34,829 · 7 patents
- Clantech, Inc. #34,830 · 7 patents
- Clarus Therapeutics, Inc. #34,832 · 7 patents
- Clean Air-engineering—maritime, Inc. #34,833 · 7 patents
- Clean Diesel Technologies, Inc. (cdti) #34,834 · 7 patents
- Clean Train Propulsion #34,835 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Clarity's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Clarity's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
47 Top 19% higher than 81% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
| 2023 | 1 | 14.3% |
| 2024 | 3 | 42.9% |
| 2025 | 1 | 14.3% |
Which technologies does Clarity Pharmaceuticals Ltd patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Frequently Asked Questions
How many patents does Clarity Pharmaceuticals Ltd hold?
Clarity Pharmaceuticals Ltd holds 7 US granted patents filed between 2021 and 2025, spanning 4 technology areas.
What is Clarity Pharmaceuticals Ltd's Innovation Score?
Clarity Pharmaceuticals Ltd has an Innovation Score of 47.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Clarity Pharmaceuticals Ltd focus on?
Clarity Pharmaceuticals Ltd's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 4 CPC subclasses total.
Is Clarity Pharmaceuticals Ltd's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Clarity Pharmaceuticals Ltd.
What does claim depth mean for Clarity Pharmaceuticals Ltd's patents?
Clarity Pharmaceuticals Ltd's patents average 21.9 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Clarity Pharmaceuticals Ltd patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Clarity's 7 grants land it in the top 19% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Clarity ranks #34,831 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.